Zinger Key Points
- Roche CEO affirmed stable or slightly increasing workforce despite recent challenges.
- Roche’s anti-obesity drug could launch by 2029, with Europe and China facing economic challenges ahead.
- Feel unsure about the market’s next move? Copy trade alerts from Matt Maley—a Wall Street veteran who consistently finds profits in volatile markets. Claim your 7-day free trial now.
Swiss pharmaceutical giant Roche Holding AG RHHBY reportedly has no plans for job cuts despite facing recent challenges in its drug development pipeline.
CEO Thomas Schinecker, in an interview with NZZ am Sonntag, reassured that worker numbers are constant to slightly increasing, reported Reuters.
He also emphasized healthy business and not having a growth problem either. Meanwhile, the report noted Schinecker saying that the company’s research and development budget remains stable without expansion.
Schinecker also provided insights into Roche’s pipeline, estimating that the company’s anti-obesity drug could hit the market by 2029 or earlier, per the report.
Addressing the broader economic landscape, Schinecker acknowledged challenges in Europe and China, contrasting them with moderate growth in the U.S.
Price Action: RHHBY shares closed at $35.07 on Friday.
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Market News and Data brought to you by Benzinga APIs© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
